As expectations grow that messenger RNA-based vaccines such as those developed by Pfizer and Moderna will dominate the Covid-19 vaccine market, analysts say there will be room for smaller players alongside those two firms.
In a note published early Monday, an analyst at Guggenheim Securities initiated coverage of CureVac (ticker: CVAC), which is developing an mRNA-based Covid-19 vaccine now in clinical trials, with a Neutral rating and no target price.
Shares…
